ICTP-301

ICTP-301 is a discovery-stage proteolysis-targeting chimera (PROTAC) drug candidate developed by InnoCure Therapeutics for the treatment of refractory solid tumors. It is designed to target and degrade SHP2 (PTPN11), a protein tyrosine phosphatase that serves as a critical signaling node in the RAS/MAPK pathway, which is frequently dysregulated in various cancers. The drug utilizes InnoCure's proprietary MILPROTAC technology, which is engineered to enhance the oral bioavailability and pharmacokinetic properties of PROTAC molecules, addressing common challenges such as large molecular size and poor absorption. ICTP-301 is being investigated for its potential in treating colorectal cancer (CRC), breast cancer, and non-small cell lung cancer (NSCLC).